+A -A

Tabela:
Comparative View:

4Q16 Create chart
Net sales revenues 1,028,665
Change in Fair Value of Biological Assets 43,135
Cost of Goods Sold -633,043
Depreciation / Amortization / exhaustion -108,874
Exhaustion of biological assets -64,596
Gross Profit 265,287
Selling Expenses -154,070
General and Administrative Expenses -34,318
Management Compensation -3,715
Other Operating Compensation 32,734
Equity income from subsidiaries -265,287
Operating Profit before Financial Income and Equity 105,918
Financial Income 28,674
Financial Expenses -107,475
Income Before Income Tax and Social Contribution 27,117
Income and social contribution taxes - current -18,321
Income Tax and Social Contribution - Deferred 16,411
Effect profit from discontinued operation -
Net Income 25,207
Recurring Net Income 6,463
Recurring EBITDA 217,107
EBITDA Margin 21.1 %

* Because of the date of the merger between Duratex and Satipel, 31.08.09, include data only from the "old" Duratex

**from 1Q 12 the data does not include discontinued operation, Deca Piazza